Ventricular Tachycardia：A Registry Study

NCT07149701 | Recruiting

• 1 other identifier: KS2025135
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.

Conditions

Ventricular Tachycardia (VT); Structural Heart Disease

Outcome Measures

Primary Outcomes (1)

• Composite of ventricular tachycardia recurrence or appropriate ICD therapy, unplanned cardiovascular hospitalization, or all-cause death

  Time to the first occurrence of ventricular tachycardia recurrence or appropriate implantable cardioverter-defibrillator (ICD) therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death.

  12 months

Secondary Outcomes (9)

• Ventricular tachycardia recurrence or appropriate ICD therapy

  12 months

• Unplanned cardiovascular hospitalization

  12 months

• Causes and number of unplanned cardiovascular hospitalizations

  12 months

• Causes and number of cardiovascular emergency department visits

  12 months

• All-cause mortality

  12 months

Study Arms (1)

SHD-VT Cohort

This cohort includes consecutive adult patients with structural heart disease and documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, enrolled in a prospective multicenter observational registry. All treatment decisions are made according to routine clinical practice without study intervention.

Other: Standard Clinical Care

Interventions

Standard Clinical Care OTHER

Participants will receive standard clinical care as determined by their treating physicians. Treatment strategies, including antiarrhythmic drug therapy, catheter ablation, implantable cardioverter-defibrillator (ICD) implantation, cardiac resynchronization therapy with defibrillator (CRT-D), surgical interventions, and other clinically indicated therapies, will be recorded. No treatment is assigned or influenced by the study protocol.

SHD-VT Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention, in the presence of structural heart disease. Participants will be consecutively enrolled from multiple hospitals in China and managed according to routine clinical practice.

You may qualify if:

• Adults aged ≥18 years.
• Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study.
• Structural heart disease diagnosed according to current clinical guidelines.
• Willing and able to provide written informed consent.
• Willing to comply with the study follow-up schedule.

You may not qualify if:

• Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances).
• Idiopathic ventricular tachycardia without evidence of structural heart disease.
• Cardiac surgery within 60 days before enrollment.
• Severe infectious diseases (e.g., septic shock or sepsis).
• Severe coagulation disorders, including platelet count \<50 × 10⁹/L or disseminated intravascular coagulation.
• Participation in another interventional clinical study that may interfere with this registry.
• Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.

Sponsors & Collaborators

• Beijing Anzhen Hospital: lead

Study Sites (1)

Beijing Anzhen Hospital, Capital Medical University

Beijing, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Biospecimens collected in this study may include, but are not limited to, whole blood, plasma, serum, peripheral blood mononuclear cells (PBMCs), and other ethically approved residual clinical specimens.

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

Tachycardia; Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Deyong Long

  Beijing Anzhen Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Deyong Long, MD

CONTACT

+86 (010) 84005361; dragon2008@vip.sina.com

Deyong Long

CONTACT

+86 (010) 84005361; dragon2008@vip.sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2025
• First Posted: September 2, 2025
• Study Start: October 14, 2025
• Primary Completion (Estimated): September 1, 2029
• Study Completion (Estimated): December 1, 2029
• Last Updated: July 29, 2026

Record last verified: 2025-08

Locations

CN (1)